141 related articles for article (PubMed ID: 8217614)
1. Repeat administration of high dose melphalan in relapsed myeloma.
Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.
Petrucci MT; Avvisati G; Tribalto M; Cantonetti M; Giovangrossi P; Mandelli F
Eur J Haematol; 1989 Mar; 42(3):233-7. PubMed ID: 2924885
[TBL] [Abstract][Full Text] [Related]
4. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
5. Double-intensive therapy in high-risk multiple myeloma.
Harousseau JL; Milpied N; Laporte JP; Collombat P; Facon T; Tigaud JD; Casassus P; Guilhot F; Ifrah N; Gandhour C
Blood; 1992 Jun; 79(11):2827-33. PubMed ID: 1350228
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
[TBL] [Abstract][Full Text] [Related]
7. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J
J Clin Oncol; 1994 Apr; 12(4):759-63. PubMed ID: 8151319
[TBL] [Abstract][Full Text] [Related]
8. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
9. High-dose melphalan for multiple myeloma: long-term follow-up data.
Cunningham D; Paz-Ares L; Gore ME; Malpas J; Hickish T; Nicolson M; Meldrum M; Viner C; Milan S; Selby PJ
J Clin Oncol; 1994 Apr; 12(4):764-8. PubMed ID: 8151320
[TBL] [Abstract][Full Text] [Related]
10. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
Fenk R; Liese V; Neubauer F; Bruns I; Kondakci M; Balleisen S; Saure C; Schröder T; Haas R; Kobbe G
Leuk Lymphoma; 2011 Aug; 52(8):1455-62. PubMed ID: 21657961
[TBL] [Abstract][Full Text] [Related]
16. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma treated with high dose intravenous melphalan.
Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
[TBL] [Abstract][Full Text] [Related]
18. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
19. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
[TBL] [Abstract][Full Text] [Related]
20. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]